

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED

和鉑醫藥控股有限公司
HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO CIRCULAR,
NOTICE OF ANNUAL GENERAL MEETING AND FORM OF PROXY FOR
USE AT ANNUAL GENERAL MEETING
TO BE HELD ON 8 JUNE 2023**

Reference is made to the circular (the “**Circular**”), the notice of annual general meeting (the “**Original AGM Notice**”) and the form of proxy (the “**Original Proxy Form**”) for use at annual general meeting to be held on 8 June 2023 (the “**AGM**”) dated 27 April 2023 of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”). Unless otherwise defined, capitalised terms used herein have the same meaning as those defined in the Circular, the Original AGM Notice and the Original Proxy Form.

Due to inadvertent clerical errors, the Company would like to clarify that:

- (i) the date and venue of the AGM appearing in the first paragraph on page 16 of the English version of the Circular and page 1 of the English version of the Original AGM Notice should be “Thursday, 8 June 2023” and “6F-7F, NO. 987, Cailun Road, Pilot Free Trade Zone, Shanghai, China”;
- (ii) the venue of the AGM appearing in the first paragraph on page 16 of the Chinese version of the Circular and page 1 of the Chinese version of the Original AGM Notice should be “中國上海自由貿易試驗區蔡倫路 987 號 6 層、7 層”;
- (iii) Principal place of business in Hong Kong appearing on page 19 of the Chinese version of the Circular and page 4 of the Chinese version of the Original AGM Notice should be “香港九龍觀塘道 348 號宏利廣場 5 樓”;
- (iv) Note (v) as set out on page 20 of the Chinese version of the Circular and page 5 of the Chinese version of the Original AGM Notice should be read as “代表委任表格連同授權書或其他經簽署(或為其經公證副本)的授權文件(如有), 最遲須於上述大會或其任何續會指定舉行時間 48 小時前(即二零二三年六月六日(星期二)上午十時前), 送交本公司之香港證券登記分處卓佳證券登記有限公司, 香港夏慤道 16 號遠東金融中心 17 樓, 方為有效。填妥及交回代表委任表格後, 本公司股東仍可依願親身出席上述大會(或其任何續會)及於會上投票。”;

- (v) Note (vi) as set out on page 20 of the Chinese version of the Circular and page 5 of the Chinese version of the Original AGM Notice should be read as “本公司將於二零二三年六月二日(星期五)至二零二三年六月八日(星期四)期間(包括首尾兩日)暫停辦理股份過戶登記手續,以釐定股東出席大會的權利,於此段期間內,本公司將不會進行任何股份過戶登記手續。為符合資格出席大會,所有股份過戶文件連同相關股票須於二零二三年六月一日(星期四)下午四時三十分前送交本公司之香港證券登記分處卓佳證券登記有限公司,香港夏慤道16號遠東金融中心17樓。”;
- (vi) Note (vii) as set out on page 20 of the Chinese version of the Circular and page 5 of the Chinese version of the Original AGM Notice should be read as “就上文第2至4項普通決議案而言,陳維維女士、裘育敏先生及王俊峰先生將於大會上退任,並符合資格及願意於上述大會上重選連任。有關上述退任董事的詳情載於隨附日期為二零二三年四月二十七日的通函附錄一。”;
- (vii) Note (vii) as set out on page 20 of the English version of the Circular and page 5 of the English version of the Original AGM Notice should be read as “In respect of ordinary resolutions numbered 2 to 4 above, Ms. Weiwei Chen, Mr. Yu Min Qiu, and Mr. Junfeng Wang shall retire at the Meeting and being eligible, have offered themselves for re-election at the Meeting. Details of the above retiring directors are set out in Appendix I to the accompanied circular dated 27 April 2023.”; and
- (viii) ordinary resolution numbered 1. as set out in the English version of the Original Proxy Form should be read as “To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor of the Company for the year ended 31 December 2022”.

Except as disclosed above, all the other information contained in the English and Chinese versions of the Circular, the Original AGM Notice and the Original Proxy Form remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Circular, the Original AGM Notice and the Original Proxy Form.

In order to facilitate the shareholders of the Company (the “**Shareholders**”) to vote on the ordinary resolution numbered 1. as set out in the Original AGM Notice and the Original Proxy Form, the Company has revised the Original Proxy Form and the Original AGM Notice. The revised form of proxy (the “**Revised Proxy Form**”) and the revised notice of AGM (the “**Revised AGM Notice**”) have been published on the Company’s website at www.harbourbiomed.com and the website of the Stock Exchange at www.hkexnews.hk on 8 May 2023, and will be dispatched to the Shareholders on or before 12 May 2023.

Shareholders who use the form of proxy must pay attention to the following:

- (1) If Shareholders have correctly completed and duly returned the Original Proxy Form, it will be deemed as the valid proxy form returned by the Shareholders. Under such circumstances, the Shareholders are not required to return the Revised Proxy Form. The proxy of the Shareholder will be entitled to vote in accordance with the instruction given by the Shareholder or at his/her discretion. If the Shareholders have correctly completed and returned the Revised Proxy Form not less than 48 hours before the time appointed for holding the AGM or any adjourned meeting, the Revised Proxy Form shall supersede and replace the Original Proxy Form previously returned by the Shareholders.
- (2) If Shareholders have not completed and returned the Original Proxy Form and wish to attend the AGM by proxy, the Shareholders are required to complete and return the Revised Proxy Form, together with the power of attorney (if any) or other authority (if any) under which it is signed, or a notarially certified copy thereof, to the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong in accordance with the instructions printed thereon not less than 48 hours before the time appointed for holding of the AGM or any adjourned meeting.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 8 May 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.